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Abstract: Type 2 diabetes mellitus (T2DM) is characterized by both insulin resistance and 
  inadequate insulin secretion. All patients with the disease require treatment to achieve and main-
tain the target glycosylated hemoglobin (A1C) level of 6.5%–7%. Pharmacological   management 
of T2DM typically begins with the introduction of oral medications, and the majority of patients 
require exogenous insulin therapy at some point in time. Primary care physicians play an essential 
role in the management of T2DM since they often initiate insulin therapy and intensify regimens 
over time as needed. Although insulin therapy is prescribed on an individualized basis, treatment 
usually begins with basal insulin added to a background therapy of oral agents. Prandial insulin 
injections may be added if glycemic targets are not achieved. Treatments may be intensified over 
time using patient-friendly titration algorithms. The goal of insulin intensification within the 
primary care setting is to minimize patients’ exposure to chronic hyperglycemia and weight gain, 
and reduce patients’ risk of hypoglycemia, while achieving individualized fasting, postprandial, 
and A1C targets. Simplified treatment protocols and insulin delivery devices allow physicians 
to become efficient prescribers of insulin intensification within the primary care arena.
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Introduction
Type 2 diabetes mellitus (T2DM) represents a vast and increasing health care crisis 
in the US. About 90% of Americans with T2DM are being managed within primary 
care practices.1 Historically, family physicians and internists have preferred to treat 
patients with oral antidiabetes medications (OADs) rather than insulin.2 Currently 
available insulin analogs may represent an important therapeutic alternative for many 
patients. Early intensification of diabetes therapies can minimize the risk of long-term 
complications associated with exposure to chronic hyperglycemia.3 The American 
Diabetes Association (ADA) estimated that in 2007, a total of US$174 billion was 
spent managing patients with diabetes, US$58 billion of which was directed towards 
managing long-term complications.4 Significant costs are attributed to prolonged 
hospital admissions, frequent outpatient and emergency department visits, and home 
health care. Diabetes-related illnesses account for 23% of inpatient costs in the US.4
Encouraging primary care physicians (PCPs) to take a more active role in becoming 
early adopters of insulin therapy would allow more patients with T2DM to experience 
less glycemic variability and symptomatic chronic hyperglycemia. One question that 
PCPs should pose to their patients with both prediabetes and diabetes is: what is the 
primary complication of well controlled diabetes? The answer, of course, is: nothing. 
Our role as physicians should be to treat patients as quickly as possible, as safely as Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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possible, to the lowest glycemic targets as possible, for as 
long as possible, and to use pharmacologic interventions as 
rationally as possible.
Overview: physiologic insulin 
replacement therapy
The balance between glucose production and utilization 
is regulated by an integrated network of hormones,   neural 
pathways, and metabolic signals. In the fasting state, insu-
lin secretion is suppressed, leading to gluconeogenesis 
  (glucose production) in the liver and kidneys accompanied 
by increased glucose generation by the breakdown of liver 
glycogen (glycogenolysis). In the postabsorptive state, 
insulin is produced and secreted from the pancreatic β 
cells, inhibiting glycogenolysis and gluconeogenesis while 
enhancing peripheral glucose uptake and utilization.   Insulin 
also inhibits lipolysis and proteolysis. The net result dur-
ing euglycemia is that excess glucose is converted into 
glycogen, triglycerides (TGs), and proteins. When more 
glucose is present in hepatocytes than can be metabolized 
or stored as glycogen, insulin converts excess glucose into 
free fatty acids (FFAs). The FFAs are packaged as TGs in 
very-low-density lipoprotein, and following plasma trans-
port into adipose tissue, are stored in fat cells to be used as 
an energy source.5
Basal insulin is produced at the rate of approximately 
1 unit (U) per hour in order to minimize the effect of hepatic 
glucose production.6 Basal insulin secretion limits lipolysis 
and FFA production; this may contribute to insulin resistance 
in the postabsorptive state. The stimulus of eating prompts 
a 5–10-fold rise in hepatic portal vein insulin concentration 
that acts to minimize postprandial hyperglycemia. Glucose-
dependent insulin secretion occurs in two phases. The first-
phase insulin response occurs quickly, over a 3–5-minute 
period5 immediately after eating, and ends rapidly, after 
approximately 5–10 minutes. First-phase insulin response 
is genetically predetermined and frequently abnormal in 
subjects with a first-degree relative with diabetes.7 Fifteen 
minutes after carbohydrates are consumed and the process 
of digestion begins, a second-phase insulin response is initi-
ated during which β cells produce and secrete insulin until all 
carbohydrates have been absorbed from the gastrointestinal 
tract and the plasma glucose levels have normalized.5 The 
second-phase insulin response plateaus in about 2–3 hours, 
yet the postabsorptive states may last up to 6 hours depend-
ing on the content of the meal.6 Prolonged exposure to even 
modestly elevated glucose has been associated with β-cell 
desensitization, increased apoptosis (β-cell death), delays 
in first-phase β-cell response to oral glucose, and attenuated 
second-phase insulin release.8
Patients with T2DM have peripheral insulin resistance 
as well as inadequate insulin secretion by pancreatic β-cells. 
During meals, the reduced first-phase insulin response results 
in postprandial hyperglycemia and a 35% decrease in hepatic 
glycogen storage.9 A 55% increase in nocturnal hepatic gly-
coneogenesis drives excessive glucose production, favoring 
fasting hyperglycemia and β-cell decompensation. Based 
on clinical investigation, observation, and work with animal 
models, β-cell decompensation progresses over five stages 
as shown in Table 1.10
Ultimately, genetically prone individuals with progres-
sive β-cell dysfunction become exposed to an ambient state 
of chronic hyperglycemia, which becomes unresponsive to 
the pharmacologic actions of OADs. Successful attainment 
of the ADA-recommended glycosylated hemoglobin (A1C) 
target of 6.5%–7.0% can only be achieved with exogenous 
insulin therapy when β-cell mass and function has been 
severely compromised.11
The significance of chronic hyperglycemia, even in the 
prediabetic state, has been demonstrated to cause micro-
vascular and macrovascular complications. In the Diabetes 
Prevention Program, diabetic retinopathy was observed in 
8% of patients with impaired glucose tolerance (IGT) and 
increased to 13% of patients who progressed to diabetes.12 
Seventy-seven patients with idiopathic peripheral neu-
ropathy demonstrated abnormal glucose metabolism when 
they received a 75 g glucose challenge. Fifty-six percent of 
patients were found to have abnormal oral glucose tolerance 
testing results, including 26 with IGT and 15 with clinical 
diabetes.13 Other potentially harmful consequences associ-
ated with chronic hyperglycemia include oxidative stress, 
endothelial dysfunction, insulin resistance, hypertension, 
and intravascular inflammation.14–17
Barriers to insulin initiation
Even modest reductions in A1C translate into meaningful 
improvements in economic and medical endpoints.18 A PCP 
who does not have access to certified diabetes educators, 
nurse practitioners, or physician assistants becomes the 
sole pharmacotherapeutic designer and educator for insulin 
initiation and intensification. To some busy practitioners, 
this may present a daunting task. As is frequently the case 
in clinical practice, insulin initiation is delayed simply 
because physicians and patients alike are susceptible to 
misconceptions and fears about disease progression and the 
role insulin plays.19Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Proposed stages of β-cell decompensation and dysregulation10
Stage Ambient blood  
glucose value
Physiologic changes  
within islet/β-cell
Histologic changes noted  
within islet/β-cell
Stage 1 85–130 mg/dL •   Lowered set-point for glucose-stimulated insulin 
 secretion due to glucokinase activation
• Normal gene expression profile 
• β-cell hypertrophy 
• β-cell hyperplasia
Stage 2 89–130 mg/dL • Loss of first-phase insulin response 
• Near-normal insulin stores
•   Decreased expression of glucokinase, glucose  
transporter proteins, and transcription factors
Stage 3 130–285 mg/dL • Loss of second-phase insulin secretion 
•   increased ratio of proinsulin: insulin, suggestive  
of β-cell injury 
•   Patient is maximally insulin resistant as 80%  
of the β-cell function is lost
• Reduced insulin stores within β-cell 
•   increased expression of genes which predispose   
to loss of β-cell mass and function 
•   in obese patients, up to 40% of the β-cell  
mass is lost
Stage 4 285–350 mg/dL • β-cell apoptosis and death • Amyloid and lipid deposits form within islets 
• Islets become fibrosed
Stage 5 .350 mg/dL • Marked β-cell destruction 
•   Loss of signaling between the α- and β-cell can  
increase risk of hypoglycemia
• Fibrosis
Table 2 Proactive questions related to hypoglycemia
• when did the event(s) occur? (daytime vs overnight)
•   Under what circumstances did they occur? (missed meal, following 
exercise, excess medication)
• what were the symptoms?
• what was the blood glucose reading?
• How did patient treat the hypoglycemia?
•   Did the patient require assistance from another person in order to 
reverse the hypoglycemia?
• Did the hypoglycemic event re-occur later within a 24-hour period?
•   what was done? (eg, carbohydrates ingested, follow-up blood  
glucose monitoring)
•   How soon did hypoglycemia resolve? (Blood glucose levels rose  
to .70 mg/dL)
• How fearful is the patient or the family of hypoglycemia?
• Do they test before driving?
•   Do patients “stack insulin” (re-bolus rapid insulin analog within  
3 hours of a similar injection)?
•   At what glycemic level does the patient perceive hypoglycemia?  
(if ,50 mg/dL, patient may have hypoglycemia-associated  
autonomic failure).
Recent randomized controlled clinical trials demonstrate 
that insulin treatment can be readily initiated and successfully 
intensified for many patients within the primary care setting. 
In fact, insulin-naïve patients have been found to be as adept 
at intensifying their own insulin regimens as are physicians, 
and PCPs just as proficient as endocrinologists at titrating 
basal insulin therapies.20–22
Patient fears present a substantial barrier to insulin 
initiation, and are commonly based on the perception that 
insulin therapy is a sign of failure.23 This concern can be 
addressed by reassuring patients that the need for insulin 
arises as a natural consequence of loss of β-cell function and 
diabetes progression. Patients who receive education about 
their individual glycemic goals (A1C , 7%; fasting plasma 
glucose [FPG] 70–130 mg/dL; 2-hour postprandial glucose 
[PPG] ,180 mg/dL) are more likely to accept insulin therapy 
as a necessary intervention.24
Fear of developing hypoglycemia as well as lack of under-
standing about how to minimize one’s risk and effectively 
manage this potentially life-threatening adverse event must 
be addressed prior to initiating insulin therapy. The reported 
incidence rates for hypoglycemia in T2DM range from 
0 to 7.3 episodes per patient-year, depending on the treat-
ment, duration of the disease and the cutpoints used to define 
severe hypoglycemia; however, when matched for duration 
of insulin therapy, the frequency of severe hypoglycemia in 
T2DM is similar to that seen in type 1 diabetes (T1DM).25,26 
Population-based data suggest that the incidence of severe 
hypoglycemia necessitating emergency medical treatment in 
insulin-treated T2DM approaches that in T1DM.27 Notably, 
because the prevalence of T2DM is approximately 20 times 
greater than that of T1DM, and because most T2DM patients 
will eventually require insulin treatment, these data suggest 
that most hypoglycemic episodes, including those of severe 
hypoglycemia, occur in patients with T2DM.
The fear of hypoglycemia may be mitigated with the use 
of structured or paired glucose testing which allows patients to 
visualize pattern recognition of glucose values and better predict 
whether hypoglycemia is imminent.28 Table 2 presents impor-
tant questions about hypoglycemia that clinicians should ask 
at every patient visit. Answers to these questions will not only 
alert clinicians to any deficits in their patients’ understanding 
of hypoglycemia (eg, causes, initiating appropriate treatment), Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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but can provide important insights regarding the potential 
cause(s) and severity of the hypoglycemia. This information, 
in turn, will allow clinicians to provide counseling to patients 
(in-office or referral to a diabetes education program) and initi-
ate necessary changes in patient treatment regimens. Regimen 
changes may include: adjusting glycemic goals (temporarily or 
for the longer term) if hypoglycemia unawareness is an issue; 
use of more appropriate medications; and initiating more fre-
quent blood glucose monitoring or use of continuous glucose 
sensing for earlier detection of hypoglycemia.
Physician barriers to initiation of insulin include con-
cerns about risks to patients and their competence for self-
  management of their disease. Time restraints exist within 
busy practices for teaching patients how to use insulin as well 
as how to effectively titrate their doses. Insulin can be safely 
and efficiently initiated within the primary care setting by a 
designated nursing assistant. Pharmaceutical companies will 
gladly provide certified diabetic educators who will demon-
strate injection techniques to office staff employees and explain 
various insulin protocols which can be passed on to patients. 
Group office visits offer another cost-effective means by which 
patients can learn to initiate and titrate insulin.29 With appropri-
ate educational efforts, patients with T2DM can successfully 
manage basal, and when necessary, prandial insulin therapy, 
under the care and supervision of PCPs (see Table 3).
The necessity of transitioning to insulin therapy does not 
imply that a patient has not been adherent to their prescribed 
lifestyle interventions. Some individuals and physicians will 
attribute their disease progression as a result of eating too 
much sugar, consuming too much alcohol, or working too 
hard and not having time to exercise. The question from 
patients that frequently arises is, “Just give me a few more 
months and I know I can turn this all around”. One response 
might be, “When diabetes is poorly controlled, the sugar 
content of the blood is very high. Sugar is sticky and this 
sugar sticks to everything; to your eyes, your kidneys, your 
blood vessels, your nerves, your joints, and your blood. If we 
don’t do something to lower the sugar content of the blood, 
not only are you likely to begin to feel sicker, you are putting 
your body at risk for long-term complications. Insulin reduces 
your blood sugar level and the blood becomes less ‘sticky’. 
The insulins we have today are not like the ones we used to 
use in the old days. They are much easier to use and you can 
even choose your own dose. Let’s get started today”.
Because T2DM is a progressive disease characterized 
by early impairment of β-cell function and ultimately loss 
of β-cell mass, insulin replacement therapy is required for 
many patients. Most OADs lose effectiveness over time, 
requiring frequent monitoring of A1C levels and adjustment 
of the treatment regimen to achieve or maintain adequate gly-
cemic control.30 As β-cell function declines further, the use 
of mealtime insulin replacement therapy must be considered 
to minimize postprandial hyperglycemic excursions which 
may impact one’s A1C.
Keys to initiating insulin therapy  
for patients with T2DM in primary care
Before initiating an insulin regimen, consider the indi-
vidual’s eating, sleeping, exercise patterns and motivation 
Table 3 Strategies for initiating and titrating insulin for treatment-
naïve patients with T2DM
•   Suggest that insulin will help patients achieve glycemic targets and 
minimize the risk of long-term complications
• Allow patients to actively participate in their insulin dose titration
•   Always praise patients on insulin at their visits for their efforts at 
achieving their glycemic targets
 ○    Remember, patients who are using insulin do not have normally 
functioning pancreases
 ○    They are performing their own insulin dose calculations, perhaps 
multiple times each day
 ○    insulin prescribers should do everything possible to help patients 
become successful users of insulin
• individualize therapy to meet the needs of each patient
 ○    Determine which treatment algorithm might work best  
for every patient
• emphasize the importance of lifestyle intervention
 ○  This should minimize weight gain and reduce PPG excursions
•   Consider group office visits to have patients meet with a certified 
diabetes educator
 ○    Often, 8–20 patients can be seen at group visits; they are time-
efficient and reimbursable by third-party payers
•   Provide each patient with an individualized, written insulin protocol to 
which they can refer
• Prescribe insulin pen devices whenever possible
 ○    Dose titration of insulin is much more accurate with pens than with 
vials and syringes
•   Teach patients how to identify and appropriately manage  
hypoglycemic events
• when initiating basal insulin, use 0.4 U/kg/day as the starting dose
 ○  Continue metformin if possible
•   if patient requires . 60 U of basal insulin per day, and his or her  
A1C level is .7%, add a rapid-acting insulin analog at the largest  
meal of the day
 ○  The dose for rapid-acting insulin is 0.1 U/kg/meal
•   if A1C level is not reduced to target after 3 months of basal plus bolus 
insulin, add a second injection at the next largest meal of the day
 ○    Repeat the A1C test at 3 months and if still above target, add a third 
mealtime injection
•   Patients on basal-bolus insulin therapy should consider modified paired 
glucose testing in order to fine-tune their treatment regimens
Abbreviations: A1C, glycosylated hemoglobin; PPG, postprandial glucose; T2DM, 
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for diabetes self-management. Availability of different 
  formulations of insulin and delivery systems permit a great 
deal of flexibility toward tailoring regimens to a patient’s 
specific needs. Optimally, insulin replacement therapy 
replicates physiologic insulin secretion in the fasting and 
postprandial states. Healthy, euglycemic individuals produce 
sufficient insulin to maintain a plasma glucose level between 
85 and 140 mg/dL.6 Thanks to exquisite and complex regula-
tory mechanisms, plasma glucose levels in healthy people 
remain within a narrow range throughout wide fluctuations 
in activity level and food intake. Coordination between 
pancreatic β-cell insulin secretion, α-cell glucagon secre-
tion, and peripheral insulin action at liver, skeletal muscle, 
and fat maintains euglycemia, the balance associated with 
the normal physiologic state.
Patient practice guidelines, such as the consensus panel 
statement of the American Association of Clinical Endo-
crinologists (AACE), suggest that insulin therapy should 
be considered in patients with T2DM and A1C $ 9% or 
for symptomatic patients with A1C $ 8.5%.31 Abundant 
evidence supports the early initiation of insulin therapy, 
as insulin acts to significantly lower plasma glucose levels 
while minimizing the long-term complications associated 
with chronic hyperglycemia.12
The Treating To Target in Type 2 Diabetes Study (the 
4-T Study), provides some insight into when insulin should 
be initiated in patients and at what time during the course 
of their disease prandial insulin might be initiated.30 Over 
700 individuals with T2DM who were on dual OAD therapy 
were randomized into this study. One group was random-
ized to biphasic insulin aspart 70/30 twice daily. The second 
group was randomized to prandial insulin aspart, three times 
daily. The third cohort was treated with basal insulin detemir 
once daily at bedtime. The trial used a clinically relevant 
protocol with clinic visits every 3 months, a schedule similar 
to that routinely followed in the primary care setting. After 
1 year, patients who continued to have unacceptable rates of 
hyperglycemia (defined as A1C . 10% after 1 measurement, 
2 consecutive A1C measurements $ 8% at or after 24 weeks 
of therapy, or an A1C . 6.5% at the end of year 1) were 
eligible for intensification of their insulin regimens. Therapy 
with a sulfonylurea was replaced with an additional type of 
rapid-acting or mixed insulin regimen as follows:
•  Aspart was added three times daily to the detemir-initiated 
arm, starting with 10% of the current total daily basal 
dose (minimum of 4 units; maximum of 6 units).
•  Detemir (10 units) was added at bedtime to the aspart-
initiated arm.
•  Aspart was added at midday to the aspart mix 70/30-
initiated arm starting with 10% of the current total 
daily dose (minimum of 4 units; maximum of 6 units). 
(This regimen is not typically prescribed in the US.)
The primary outcome of the first 4-T Study published 
in 200732 was A1C. There were small but significant differ-
ences between the three groups. The group with the highest 
A1C was those individuals randomized to basal insulin 
at bedtime, and those with the lowest A1C had received 
prandial insulin. However, none of the groups achieved the 
target A1C of ,6.5%. As one would expect, basal insulin 
resulted in optimal reduction of FPG, whereas prandial insu-
lin improved postmeal glucose excursions better than basal 
or mixed insulins. Less weight gain and fewer episodes of 
hypoglycemia were noted in the basal insulin cohort. Thus, 
after 1 year, the 4-T conclusions were as follows: (1) regi-
mens using biphasic or prandial insulin reduced A1C to a 
greater extent than basal but were associated with a greater 
risk of hypoglycemia and weight gain; (2) most patients are 
likely to require more than one type of insulin to achieve 
target A1C levels over time, as very few individuals were 
able to maintain their A1C levels , 6.5%.
Because the investigators noted a progression in the dis-
ease process for their patients with T2DM and an inability to 
reduce A1C levels, patients were randomized to be placed on 
prandial insulin. After 2 additional years in the 4-T study, the 
A1C levels were identical between all three groups. What did 
reach statistical significance was the fact that those individu-
als initiated on basal insulin monotherapy at the end of 3 years 
had less grade 2 or grade 3 hypoglycemia (the more severe 
forms of hypoglycemia). This group also demonstrated the 
least amount of weight gain during the 3-year study.
The overall aggregate A1C level at the conclusion of the 
3-year 4-T study was 6.9% and did not differ significantly 
between treatment groups. However, patients commencingth-
erapy with basal or prandial insulin more often achieved glyce-
mic targets than those initiating therapy with biphasic insulin. 
The lowest weight gain and lowest rate of hypoglycemia 
occurred in the detemir + aspart group, with 63% of patients 
achieving A1C # 7%. Finally, the 4-T Study supports start-
ing insulin therapy with once-daily basal insulin and adding 
prandial insulin if glycemic goals are not met within 1 year.
Basal insulin was the most effective treatment regimen 
within the 4-T protocol because the insulin dose was progres-
sively increased towards specific fasting and postmeal targets. 
Self-monitored blood glucose values of each subject were ana-
lyzed by a computer management system at the time of each 
visit. An insulin dosing regimen was then prescribed to target Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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FPG levels of 72–99 mg/dL and 2-hour postprandial levels of 
90–126 mg/dL. Investigators and patients were encouraged to 
vary suggested insulin doses, as clinically appropriate, and to 
amend the doses between visits.   Hypoglycemia was catego-
rized as grade 1 (symptoms only) if a patient had symptoms 
with a self-measured capillary glucose level of 56 mg/dL 
or more, grade 2 (minor) if the patient had symptoms with 
a self-measured capillary glucose level of less than 56 mg/
dL, or grade 3 (major) if third-party assistance was required. 
Unfortunately, the computer-generated dosing protocol sug-
gestions are not clinically available to practicing physicians 
and were used solely for those investigators and patients 
enrolled in the 4-T study. Nevertheless, initial intensification 
of therapy in patients with poorly controlled T2DM with basal 
insulin appears to be a prudent choice. Fasting hyperglycemia 
contributes more than postprandial hyperglycemia to A1C 
levels during periods of poor glycemic control.33
Other studies have compared the two basal insulin analogs 
(insulin detemir and insulin glargine) as background for the 
addition of mealtime prandial insulin. Two trials sought to 
demonstrate the noninferiority of insulin determir to insulin 
glargine in a basal-bolus treatment regimen that included 
insulin aspart as the prandial component. Hollander and col-
leagues included 319 patients with T2DM who were random-
ized to 52 weeks of treatment with insulin detemir or insulin 
glargine.34 Basal insulin doses were adjusted to a prespecified 
algorithm according to FPG levels. Both regimens produced 
similar marked decreases in mean A1C levels from baseline 
(-1.52% for insulin detemir and -1.68% insulin glargine). 
There were no significant differences in the development of 
hypoglycemia or adverse events. However, patients treated 
with insulin detemir experienced significantly less weight 
gain as compared with insulin glargine (2.8 kg with insulin 
detemir, 3.8 kg with insulin glargine; mean difference -1.04; 
95% confidence interval, -2.08 to -0.01; P , 0.05).
A similar study included 385 T2DM patients random-
ized to treatment with either insulin detemir or insulin 
glargine plus prandial insulin aspart, for 26 weeks.35 Both 
basal insulins produced similar significant (P , 0.001) 
decreases in mean A1C levels at 26 weeks vs baseline (-1.1% 
for insulin detemir; -1.3% for insulin glargine). The rates 
of hypoglycemic events were comparable between groups. 
Again, the patients randomized to receive insulin detemir 
experienced significantly less weight gain than did those 
treated with glargine (1.2 ± 3.96 kg with insulin detemir; 
2.7 ± 3.94 kg with glargine; P = 0.001). These trials   confirm 
that a   basal-bolus insulin regimen utilizing either basal 
insulin, together with the rapid-acting insulin aspart given at 
every meal, provides safe and effective treatment for effective 
glycemic control in patients with T2DM.
Intensification of insulin therapy
Basal insulin therapy may help patients achieve glycemic 
goals for a time, but predictable and progressive pancreatic 
β-cell dysfunction necessitates the eventual addition of 
mealtime insulin to minimize postprandial hyperglycemia.36,37 
Glucose fluctuations during the postprandial period elicit more 
oxidative stress than chronic, sustained hyperglycemia, which 
can lead to endothelial dysfunction, vascular inflammation, 
atherosclerosis, and microvascular complications.38,39 Pharma-
cologic interventions with insulin analogs reduce oxidative 
stress and vascular inflammation and improve endothelial 
function.40 Insulin intensification in patients with T2DM is 
also cost-effective and has been associated with a marked 
decrease in health care costs, due to diminished use of OADs, 
and with significantly fewer inpatient hospitalizations.41
Rapid acting insulin analogs exhibit a peak onset of 
pharmacodynamic activity at 60 minutes postinjection. Peak 
carbohydrate absorption following a meal occurs at approxi-
mately 75–90 minutes after eating begins. Therefore, in order to 
synchronize the peak activity of insulin with the expected rise 
in PPG, the analog should be injected 15 minutes prior to the 
meal unless the blood glucose level is ,80 mg/dL.42 This delay 
between the injection and onset of the consumption of the meal 
is known as the “insulin lag time”. Patients who inject just prior 
to a meal may experience postprandial hyperglycemia although 
they have calculated their insulin dose appropriately.
If one is uncertain as to which meal should be targeted 
for intervention, “structured” glucose testing should be 
performed for 3 days prior to and 2 hours after each meal. 
The meal with the highest “delta” (the difference in blood 
glucose values between premeal and 2-hour postprandial 
levels) becomes the initial point of intercession.
Choosing the most appropriate meal to initiate prandial 
insulin may be inconsequential. A study investigating the 
efficacy of injecting the rapid-acting insulin analog glulisine 
at either breakfast or at the main mealtime in patients with 
T2DM on a background insulin glargine plus OADs resulted 
in significant improvement in A1C levels regardless of meal 
specificity.43
If after 3 months the A1C is not approaching the recom-
mended target, structured glucose testing should be repeated 
for 3 days. First, evaluate the “delta” for the meal during 
which the initial intervention was initiated. The average 
delta should be #50 mg/dL, which is considered to be 
“physiologic”.44 If the delta is significantly greater than Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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50 mg/dL, consider increasing the baseline dose of prandial 
insulin at that meal until the 2-hour postprandial glucose 
level is ,50 mg/dL from baseline. One could also con-
sider adding a second mealtime injection of a rapid-acting 
insulin analog at either breakfast or lunch. The initial dose 
of any prandial rapid-acting insulin can be approximated 
as 0.1 units/kg/meal. Thus, a 100-kg person would require 
10 U of a rapid-acting analog, which would be injected 
15 minutes prior to eating. If the 2-hour postprandial glucose 
is #50 mg/dL, the correct amount of insulin was given to 
cover the carbohydrate content of that meal. However, if the 
2-hour postprandial glucose level is consistently .50 mg/dL, 
the patient can adjust the mealtime dose of insulin by 1 U 
per day until the targeted delta is achieved.45
A single prandial insulin dose may not allow all patients to 
reach one’s targeted A1C level. Therefore, .50% of patients 
require basal-bolus insulin, implying that injections be given 
prior to each meal. Several strategies have been implemented in 
order to develop effective treatment intensification schedules. 
For example, Meneghini and colleagues evaluated the stepwise 
addition of prandial insulin aspart in a randomized, controlled, 
parallel group, open-label, 48-week trial (STEPwise™) that 
included 296 subjects with T2DM who were inadequately 
controlled on basal insulin and OADs.46 The objective of the 
trial was to compare sequential addition of insulin aspart to (1) 
the largest meal with titration based on premeal glucose values, 
identified as “SimpleSTEP” or addition of insulin aspart to 
(2) the meal with the largest prandial glucose increment with 
titration based on postmeal values, labeled “ExtraSTEP”. Fol-
lowing an initial 12-week run-in period during which OADs 
were continued and basal insulin detemir was optimized, 
patients had treatment with prandial insulin initiated at their 
largest meal. After another 12 weeks, patients who had not 
achieved A1C , 7% added aspart at the next largest meal, and 
such additions were made every 12 weeks among patients who 
still had A1C $ 7%. By the end of the 48-week trial, .75% 
of the patients were receiving three insulin aspart injections 
per day.46 A1C had decreased by 0.5% in period 1, by a fur-
ther 0.5% in period 2, and by 0.2% in period 3 in both arms 
(Table 4). At the completion of the trial, there were no statis-
tically significant differences in A1C, hypoglycemia, weight, 
or treatment satisfaction. The investigators concluded that the 
SimpleSTEP and ExtraSTEP algorithms are equally effective 
strategies for intensifying therapy by adding insulin aspart to 
insulin detemir among patients with T2DM (Table 4).
Choosing the optimal insulin 
intensification protocol
Although a basal-bolus insulin regimen (once-daily insu-
lin glargineor insulin detemir plus a rapid-acting insulin 
analog: lispro, aspart, or glulisine) mimics the physiologic 
action of endogenous insulin secretion, many individuals 
may be reluctant to initiate multiple daily injections. Thus, 
prescribers should match the insulin regimen to the patient’s 
needs, concerns, and requests. As insulin is initiated, the 
glycemic targets for fasting, postprandial and A1C targets 
must be addressed. Self-dosing titration algorithms for both 
basal and prandial insulin should be provided to the patient. 
Stepwise intensification may promote patient acceptance 
and enhance adherence with insulin therapy. Insulin titra-
tion should be performed using pen devices rather than 
vials and syringes as pens are simple to use, demonstrate 
accurate dosing, and can provide titrations of 1, 2, or 3 U 
per meal with a simple twist of a dial. The 32-gauge needles 
used in pen delivery systems are virtually painless.
Multiple daily injections of insulin may be required for 
patients with acute glucose toxicity (FPG . 250 mg/dL).47 Once 
the glucose levels normalize, a decision can be made to either 
maintain insulin intensification, place the patient on an incretin 
mimetic (glucagon-like peptide-1 receptor agonist or dipeptidyl 
peptidase-4 inhibitor) or reduce the number of injections the 
patient is receiving while maintaining the use of OADs.
Table 4 SimpleSTeP™ or extraSTeP algorithm46
Efficacy Period 1 Period 2 Period 3 Period 1 Period 2 Period 3
SimpleSTEP ExtraSTEP
A1C (%) 8.2 7.7 7.6 8.5 7.9 7.7
FPG (mmol/L)  8.2 7.6 7.6 8.0 7.6 7.4
Hypoglycemia (episodes/yr)
Requiring assistance 0 0 0.14 0.03 0 0
No assistance
PG , 3.1 mmol/L 3.5 6.1 8.8 3.3 5.5 9.3
weight change at  
end of trial (kg)
2.7 2.0
Abbreviations: A1C, glycosylated hemoglobin; FPG, fasting plasma glucose; PG, plasma glucose.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Patients who are initiated on basal insulin on a back-
ground of OADs can use the Canadian Insight Trial   protocol. 
Basal insulin is initiated at 10 U, taken at the same time 
each night, and increased by 1 U daily until the fasting 
glucose levels are , 99 mg/dL.48 Lowering fasting glucose 
levels .100 mg/dL will result in concurrent improvement in 
postprandial excursions, reduce glucotoxicity, and improve 
β-cell function. Once fasting glucose levels are normalized, 
further increasing the basal dosage will not improve any per-
sistent rise in postprandial hyperglycemia. Prandial injections 
of insulin should be prescribed when $60 U of basal insulin 
is required to achieve normalization of fasting glucose or 
when postprandial glucose values exceed 180 mg/dL when 
the patient’s morning glucose levels are euglycemic. The 
A1C should be monitored again after 3 months. If the A1C 
level remains above target, another mealtime insulin injection 
should be added before the second largest meal of the day. If, 
after 3 additional months, the A1C level still remains elevated, 
a third mealtime injection should be advised.
Conclusion
Insulin therapy provides many benefits to patients with T2DM. 
With significant improvements in glycemic control, long-term 
complications of diabetes and their associated costs may be 
markedly reduced. Insulin analogs facilitate insulin dosing and 
reduce the risks of hypoglycemia and weight gain. Patients 
can readily learn treatment algorithms necessary to safely and 
effectively reach glycemic targets. PCPs can manage these 
patients, and referral to specialists may be minimized. Patients 
failing to achieve glycemic goals with basal insulin and OADs 
may require addition of prandial insulin. Intensification may 
be accomplished using a basal-bolus approach, by starting 
with prandial insulin at every meal, or more gradually, initially 
targeting one meal, with insulin added subsequently at other 
meals based on individualized glycemic goals. The safety and 
efficacy of different intensive insulin treatment algorithms, 
many of which have been clinically tested within the primary 
care arena, are clear. These findings should provide PCPs the 
tools they need to become more effective prescribers of treat-
ments directed towards successful management of patients 
with poorly controlled T2DM.
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